Is Suven Pharmaceuticals a good stock to invest in?

Suven Pharmaceuticals can be analyzed on the following key metrics - TTM P/E: - Sector P/E: - Dividend Yield: - D/E ratio: -

Suven Pharmaceuticals Share Price

Powered by

0.00 0.00 (0.00%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 0.00

Today’s High 0.00

52 Week Low

52 Week High

Key Metrics

Open Price 0
Prev Close 0

View All Metrics

Suven Pharmaceuticals Analysis

Risk Meter

40% Low risk
40% Moderate risk
40% Balanced Risk
40% High risk
40% Extreme risk

Suven Pharmaceuticals News

Premium

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy

1 min read . 03 Mar 2025

Premium

Stocks to Watch: Suven Pharma, Reliance Power, Laurus Labs, Paytm, and more

3 min read . 09 Dec 2024

Premium

Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY

1 min read . 13 Nov 2024

Stocks market today: Experts have recommended buying these four shares — Suven Pharmaceuticals, Indigo Paints, Mahindra and Mahindra Financial Svcs, and Torrent Pharmaceuticals. (Unsplash)

Premium

Stock market today: Experts recommend four stocks to buy or sell on Tuesday

5 min read . 22 Oct 2024

View More News

Suven Pharmaceuticals Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
1051.35

Selling/ General/ Admin Expenses Total
159.66

Depreciation/ Amortization
54.5

Other Operating Expenses Total
50

Total Operating Expense
700

Operating Income
351.35

Net Income Before Taxes
405.67

Net Income
300.28

Diluted Normalized EPS
11.89

Period
2023

Total Revenue
1340.33

Selling/ General/ Admin Expenses Total
134.95

Depreciation/ Amortization
47.73

Other Operating Expenses Total
61.91

Total Operating Expense
821.52

Operating Income
518.81

Net Income Before Taxes
559.73

Net Income
411.29

Diluted Normalized EPS
16.16

Period
2022

Total Revenue
1320.22

Selling/ General/ Admin Expenses Total
128.12

Depreciation/ Amortization
39.1

Other Operating Expenses Total
51.84

Total Operating Expense
779.69

Operating Income
540.53

Net Income Before Taxes
667.59

Net Income
453.8

Diluted Normalized EPS
17.83

Period
2021

Total Revenue
1009.72

Selling/ General/ Admin Expenses Total
102.81

Depreciation/ Amortization
31.64

Other Operating Expenses Total
40.03

Total Operating Expense
600.87

Operating Income
408.84

Net Income Before Taxes
467.67

Net Income
362.34

Diluted Normalized EPS
14.23

Period
2020

Total Revenue
833.79

Selling/ General/ Admin Expenses Total
101.55

Depreciation/ Amortization
23.86

Other Operating Expenses Total
27.43

Total Operating Expense
472.52

Operating Income
361.27

Net Income Before Taxes
404.51

Net Income
317

Diluted Normalized EPS
12.45

Period
2019

Total Revenue
377.83

Selling/ General/ Admin Expenses Total
47.75

Depreciation/ Amortization
11.5

Other Operating Expenses Total
13.15

Total Operating Expense
215.09

Operating Income
162.74

Net Income Before Taxes
157.87

Net Income
109.27

Diluted Normalized EPS
4.29

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Suven Pharmaceuticals Technical

Moving Average SMA

5 Day1071.76
10 Day1084.58
20 Day1127.85

50 Day1136.59
100 Day1122.24
300 Day1145.54

Suven Pharmaceuticals Peers

Price
Ratio

Suven Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

28-May-25
Audited Results

12-Feb-25
Quarterly Results

12-Nov-24
Quarterly Results

09-Aug-24
Quarterly Results

30-May-24
Audited Results

05-Feb-24
Quarterly Results

09-Nov-23
Quarterly Results

08-Aug-23
Quarterly Results

25-May-23
Audited Results

06-Feb-23
Quarterly Results

Meeting Date
Announced on
Purpose

19-Dec-24
21-Nov-24
POM

28-Nov-24
28-Oct-24
COM

09-Aug-24
15-Jul-24
AGM

15-Feb-24
12-Jan-24
POM

15-Dec-23
10-Nov-23
AGM

14-Dec-23
13-Nov-23
POM

18-Aug-22
09-May-22
AGM

31-Aug-21
08-Jun-21
AGM

Announced on
Record Date
Ex-Dividend
Dividend Value

29-Aug-22
12-Sept-22
09-Sept-22
1

30-Aug-22
12-Sept-22
09-Sept-22
5

02-May-22
17-May-22
13-May-22
1

03-May-22
17-May-22
13-May-22
1

01-Feb-22
16-Feb-22
15-Feb-22
1

02-Feb-22
16-Feb-22
15-Feb-22
2

08-Jun-21
17-Aug-21
13-Aug-21
1

03-Feb-21
18-Feb-21
17-Feb-21
1

View All

SUVEN PHARMACEUTICALS SUMMARY

Suven Pharmaceuticals is trading 0.00% lower at Rs 0.00 as compared to its last closing price. Suven Pharmaceuticals has been trading in the price range of 0.00 & 0.00.

The company posted a net profit of 82.88 Crores in its last quarter.

Suven Pharmaceuticals has a 50.1% promoter holding & 49.9% public holding.

FAQs about Suven Pharmaceuticals

Suven Pharmaceuticals is trading at 0.00 as on -. This is 0.00% lower as compared to its previous closing price of 0

The market capitalization of Suven Pharmaceuticals is - as on -.

The 52 wk high for Suven Pharmaceuticals is - whereas the 52 wk low is -

Suven Pharmaceuticals can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: -
Dividend Yield: -
D/E ratio: -

Suven Pharmaceuticals reported a net profit of 300.28 Cr in 2024.

Suven Pharmaceuticals Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Suven Pharmaceuticals Share Price

Price Range

Price Range

Key Metrics

Suven Pharmaceuticals Analysis

Suven Pharmaceuticals News

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy

Stocks to Watch: Suven Pharma, Reliance Power, Laurus Labs, Paytm, and more

Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY

Stock market today: Experts recommend four stocks to buy or sell on Tuesday

Suven Pharmaceuticals Financials

Forecast

Forecast

Forecast

Suven Pharmaceuticals Technical

Suven Pharmaceuticals Peers

Suven Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

SUVEN PHARMACEUTICALS SUMMARY

FAQs about Suven Pharmaceuticals

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue